The Daily Mail reports on a personal account in which the author says she stops taking Mounjaro and begins using retatrutide (“reta”) sourced from a dealer via WhatsApp. The article describes her first delivery and frames the peptide as a “triple-action” weight-loss drug.
The piece also says her use leads to side effects severe enough that she ends up in A&E. It characterizes obtaining retatrutide outside formal supply chains as more complex than using legal injections, but it does not provide verifiable, clinical details about dosing, purity, or prescribing.
Across the two provided sources (both from the same outlet network), the emphasis remains on the author’s experience with black-market sourcing and the resulting adverse effects. No other outlets or independent reporting are included here, so there is limited context on how common such outcomes are, and no corroboration from regulators or medical professionals is present in the excerpts.
